Target intelligence / Profile preview

Complement C3dg fragment (C3dg)

Target
C3dg
Molecular classification
Other
01

Overview

Complement C3dg is a stable, long-lived proteolytic cleavage fragment of complement component 3 (C3) that remains covalently bound to cell surfaces and tissues at sites of complement activation. It is generated when C3b is sequentially cleaved by factor I and its cofactors into iC3b, and subsequently into C3dg and C3c. C3dg plays a critical role in bridging innate and adaptive immunity by interacting with complement receptor 2 (CR2/CD21) on B cells to lower the threshold for B cell activation, and with complement receptor 3 (CR3) on phagocytes to facilitate opsonization and phagocytosis. Because of its covalent attachment and prolonged tissue residence time, C3dg serves as an attractive target for tissue-localized complement inhibitors, such as ADX-097 (AKB-097) and TT30. These therapeutic fusion proteins utilize C3dg/C3d-binding domains to deliver complement regulatory proteins (like Factor H) directly to damaged tissues, thereby selectively inhibiting the complement cascade locally while preserving systemic complement activity and reducing the risk of systemic infections.

Other names
C3dgComplement C3d,gC3d,g fragmentC3d,gComplement component 3dg
02

Mechanism of action

Tissue-targeted complement inhibition by binding to C3dg/C3d deposited at sites of complement activation, delivering a complement regulatory domain (such as Factor H) to locally inhibit the alternative pathway convertases without causing systemic complement blockade.

03

Biological functions

Immune responseOther
04

Disease associations

InflammationInfectionOther
05

Safety considerations

Risk of localized or systemic infections (though minimized compared to systemic complement inhibitors)Potential immunogenicity (anti-drug antibodies)Risk of autoimmune reactions if complement clearance of immune complexes is altered
06

Interacting drugs

ADX-097 (AKB-097)

1 more in the full profile.

07

Biomarkers

C3dg deposition in tissuePlasma C3dg levelsC3dg/C3 ratioUrine protein-to-creatinine ratio (uPCR)Estimated glomerular filtration rate (eGFR)

Beyond the preview

Go deeper on Complement C3dg fragment (C3dg).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Complement C3dg fragment (C3dg).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call